Qi Wen Chen

20030124745, Jul 3, 2003

Nov 19, 2002

10/298947

Qi Chen - San Gabriel CA, US

G01N033/553

436/526000

A method for detecting the occurrence of a biological reaction or quantitating its result employing superparamagnetic particles is disclosed. The particles are first conjugated or adsorbed to identical biomolecules which are members of a biological binding pair and the conjugates or adsorbates so formed are then contacted with a liquid or solid sample known to contain, or suspected of containing, molecules that are the biological binding partners of the biomolecules in the conjugates or adsorbates. The conjugates or adsorbates are contacted with the liquid or solid sample for a time sufficient to enable the formation of a tightly bound, three-dimensional mass comprised of interlinked biomolecules and bound superparamagnetic particles. The mass was exposed to the magnetic field of an experimental instrument for the shortest period necessary to induce magnetization of the superparamagnetic particles, whereupon the magnetic field was immediately removed. It was found that the mass exhibited a measurable nonpermanent magnetization which persisted for at least 20 minutes following exposure to the magnetic field. Experiments were later performed using a SQUID instrument having a constant magnetic field that cannot be switched off during measurements. These experiments confirmed that a measurable non-permanent aggregative magnetization remains in the sample, albeit for a shorter time period. They also showed that the effect persists for a longer period when the sample is kept wet after magnetization than when the sample is allowed to dry thereafter.

20130115193, May 9, 2013

Nov 8, 2012

13/672266

Bristol-Myers Squibb Company - Princeton NJ, US
John A. Bender - Middletown CT, US
Zhong Yang - Southington CT, US
Makonen Belema - North Haven CT, US
Omar D. Lopez - Wallingford CT, US
Qi Chen - Elmhurst NY, US
Gan Wang - Cheshire CT, US
Piyasena Hewawasam - Middletown CT, US

Bristol-Myers Squibb Company - Princeton NJ

C07D 403/14
A61K 31/4545
C07D 401/14
A61K 31/437
C07D 471/04
A61K 31/4985
C07D 487/04
C07D 405/14
A61K 31/498
A61K 31/4178
A61K 31/4375
A61K 31/4709
A61K 31/5377
C07D 413/14
C07D 403/10
A61K 45/06
A61K 31/4184

424 852, 424 857, 514394, 5483054, 514316, 546187, 514303, 546118, 514249, 544350, 5483131, 544353, 514397, 546122, 514300, 546167, 514314, 5142322, 544 82, 5483137, 514 43, 514 44 A

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

20130121957, May 16, 2013

May 7, 2012

13/465298

Qi Chen - Stamford CT, US
Omar D. Lopez - Wallingford CT, US
John A. Bender - Middletown CT, US
Gan Wang - Cheshire CT, US
Van N. Nguyen - Meriden CT, US
John F. Kadow - Wallingford CT, US
Nicholas A. Meanwell - East Hampton CT, US
Makonen Belema - North Haven CT, US

C07D 403/14
A61K 45/06
A61K 31/4184
A61K 31/5377
A61K 31/4178
C07D 405/14

424 852, 514397, 5483007, 5483121, 514394, 5142322, 544 70, 424 854, 514 43, 514 44 A, 5483131, 424 857, 514293

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

20140018389, Jan 16, 2014

Sep 16, 2013

14/027531

John A. Bender - Middletown CT, US
Jeffrey Lee Romine - Meriden CT, US
Edward H. Ruediger - Greenfield Park, CA
Carol Bachand - Candiac, CA
Omar D. Lopez - Wallingford CT, US
Qi Chen - Elmhurst NY, US
Makonen Belema - North Haven CT, US
John F. Kadow - Wallingford CT, US
Lawrence G. Hamann - North Grafton MA, US

C07D 417/14
C07D 405/14
C07D 401/14
C07D 403/14
C07D 409/14
C07D 413/14

514316, 5483131, 514397, 548204, 514365, 548236, 514374, 546187, 5483121

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

20190372041, Dec 5, 2019

Aug 13, 2019

16/539589

- Oakland CA, US
Qi Chen - Los Angeles CA, US
Huanping Zhou - Los Angeles CA, US

The Regents of the University of California - Oakland CA

H01L 51/42
B05D 1/00
H01L 51/00

According to some embodiments of the present invention, a method of producing an organic-inorganic perovskite thin film includes depositing a layer of inorganic material on a substrate to form an inorganic film, and performing an organic vapor treatment of the inorganic film to produce an organic-inorganic perovskite thin film. The layer of inorganic material comprises an inorganic anion layer having a metal-ligand framework, and the organic vapor treatment provides organic cations capable of becoming inserted into the metal-ligand framework of the inorganic anion layer to form a perovskite structure.

20180096796, Apr 5, 2018

Apr 20, 2016

15/567721

- Oakland CA, US
Yongsheng Liu - Los Angeles CA, US
Qi Chen - Los Angeles CA, US
Huanping Zhou - Los Angeles CA, US

The Regents of the University of California - Oakland CA

H01G 9/20
H01G 9/00
H01L 51/00
H01L 51/42
H01L 51/44

An optoelectronic device includes a first electrode, a second electrode spaced apart from the first electrode, a photoactive layer that includes an organic-inorganic hybrid perovskite material disposed between the first and second electrodes, and a layer of a hole transport material disposed between the photoactive layer and one of the first and second electrodes. A method of producing an optoelectronic device includes forming a photoactive layer of an organic-inorganic perovskite using at least one of solution processing or thermal vacuum deposition, and depositing a layer of hole transport material on the photoactive layer using at least one of solution processing or thermal vacuum deposition. The hole transport material includes non-doped donor-acceptor (D-A) conjugated small molecules.

20160285021, Sep 29, 2016

Nov 12, 2014

15/036023

- Oakland CA, US
Qi Chen - Los Angeles CA, US
Huanping Zhou - Los Angeles CA, US

The Regents of the University of California - Oakland CA

H01L 51/42
B05D 1/00
H01L 51/00

According to some embodiments of the present invention, a method of producing an organic-inorganic perovskite thin film includes depositing a layer of inorganic material on a substrate to form an inorganic film, and performing an organic vapor treatment of the inorganic film to produce an organic-inorganic perovskite thin film The layer of inorganic material comprises an inorganic anion layer having a metal-ligand framework, and the organic vapor treatment provides organic cations capable of becoming inserted into the metal-ligand framework of the inorganic anion layer to form a perovskite structure.

20150322048, Nov 12, 2015

Jul 23, 2015

14/807084

- Princeton NJ, US
John A. Bender - Middletown CT, US
Zhong Yang - Southington CT, US
Makonen Belema - North Haven CT, US
Omar D. Lopez - Wallingford CT, US
Qi Chen - Elmhurst NY, US
Gan Wang - Cheshire CT, US
Piyasena Hewawasam - Middletown CT, US

C07D 403/14
A61K 45/06
A61K 31/4178
A61K 31/4545
C07D 471/04
A61K 31/437
C07D 487/04
A61K 31/4985
C07D 405/14
C07D 401/14
A61K 31/4709
A61K 31/498
A61K 31/4375
C07D 413/14
A61K 31/5377
A61K 31/4184

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.